Loading...
•
Dec 28, 2019
Haemonetics Q3 2020 Earnings Report
Haemonetics reported third quarter fiscal year 2020 results, reaffirming revenue guidance and raising all other guidance for fiscal year 2020.
Key Takeaways
Haemonetics reported a 4.7% increase in revenue compared to the third quarter of fiscal year 2019. The company's value drivers are powering revenue and earnings growth, and they are transforming their product portfolio, reducing complexity, and advancing operational excellence.
Third quarter fiscal 2020 revenue was $259.0 million, up 4.7% compared with the third quarter of fiscal 2019.
Third quarter fiscal 2020 net income was $29.9 million, up $11.6 million or 63.6%, and earnings per diluted share was $0.58, up 65.7% when compared with the third quarter of fiscal 2019.
Third quarter fiscal 2020 adjusted net income was $48.5 million, up $15.1 million or 45.1%, and adjusted earnings per diluted share was $0.94, up 49.2% when compared with the third quarter of fiscal 2019.
The Company reaffirmed its GAAP total revenue guidance of 3 – 5% and organic revenue guidance issued on November 1, 2019.
Haemonetics
Haemonetics
Haemonetics Revenue by Segment
Revenue by Segment
Plasma Revenue
CapyFin.comBlood Center Revenue
CapyFin.comHospital Revenue
CapyFin.com Forward Guidance
The Company raised its adjusted operating margin, adjusted earnings per diluted share and free cash flow before restructuring and turnaround guidance.
Positive Outlook
- Adjusted operating margin ~22%
- Adjusted earnings per diluted share $3.30 - $3.40
- Free cash flow, before restructuring & turnaround $125-$150 million
- Fiscal 2020 earnings guidance includes estimated benefits from the Complexity Reduction Initiative
- Fiscal 2020 earnings guidance includes estimated benefits from the Operational Excellence Program and the share repurchase program.
Revenue & Expenses
Visualization of income flow from segment revenue to net income